Marisa Wexler, MS, senior science writer —

The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency “urges the companies to review all claims made for their…

New guidelines from the American Academy of Neurology (AAN) recommend that people with multiple sclerosis (MS) keep up with regular vaccinations, including annual flu shots, but be sure to first advise their doctor on medications they are using. The guidelines were published in the journal Neurology, in the report…

The first in-human clinical trial of EHP-101, an investigational treatment for multiple sclerosis (MS) and systemic scleroderma (SSc), has been successfully completed, Emerald Health Pharmaceuticals (EHP) announced. EHP-101 demonstrated it was safe and well-tolerated in healthy volunteers, supporting further clinical development of EHP-101 in future Phase 2 clinical trials. The…

Imaging techniques that measure damage to the brain, in addition to those that detect lesions, may be useful in predicting likely disease progression in people with clinically isolated syndrome (CIS), a study found. The study, “Early imaging predictors of longer term multiple sclerosis risk and severity…

The National Health Service (NHS) England announced an initiative that aims to speed diagnoses and ensure better all-around care for people with progressive neurological conditions like multiple sclerosis (MS), Parkinson’s disease, and motor neuron disease (MND). Experts at NHS England, as part of the NHS RightCare…

Medications for treating certain rare and chronic conditions,  including multiple sclerosis (MS), are now available from the specialty and home delivery pharmacy AllianceRx Walgreens Prime, the company announced. The newly included specialty medications are all limited distribution drugs (LDDs), which means the drug manufacturers have signed agreements giving very…

Opioid addiction increases the risk for a number of physical and psychological problems in people with multiple sclerosis (MS), a new study has found. The study, “Impact of opium dependency on clinical and neuropsychological indices of multiple sclerosis patients,” was published in the journal Neurological Sciences. Opioids,…

Smartphones could be used as an inexpensive and effective way to measure  tremors in mice, which may allow for more research on tremor medications, a new study reports. The study, “Accurate and affordable assessment of physiological and pathological tremor in rodents with the accelerometer of a smartphone,”…

People listening to music during an extended walk tend to sync their steps to its beat — and for those with multiple sclerosis (MS), such synchronization helps to overcome mental fatigue and improve motivation, a study found. “Continuous 12 min walking to music, metronomes and in silence:…

An antiviral medication called amantadine and ondansetron, which treats chronic nausea, both work to reduce fatigue in people with multiple sclerosis (MS), but amantadine may be more effective, a single-site trial in Iran reports. The study, “Comparison of the effects of amantadine and ondansetron in treatment…

Convelo Therapeutics has announced a collaboration with Genentech, a member of the Roche Group, to work toward the development of new remyelination therapies for multiple sclerosis (MS) and other myelin disorders. “We are excited to be working with Genentech to…

A new study demonstrates that intracellular sigma peptide (ISP) can promote remyelination in a mouse model of multiple sclerosis (MS). Importantly, this study was independent of NervGen, a pharmaceutical company that is developing an ISP-like compound — NVG-291 — for the treatment of nerve injury and MS. The study,…

Two researchers at Kessler Foundation were awarded grants of $35,000 each by the New Jersey Health Foundation to pursue their investigations into new ways to improve rehabilitative care for disabilities caused by multiple sclerosis (MS) and stroke. One of the awardees…

Inhibiting the function of a protein called sortilin — an important regulator of nerve damage-induced pain in mice — may represent a potentially effective strategy for treating chronic pain in humans, including those with multiple sclerosis, a study in mice suggests. The researchers say more work is needed…

The loss of immune B-cells, and the resulting changes in the profile of immune T-cells, is a major mechanism of action for the beneficial effects seen with ublituximab treatment in multiple sclerosis (MS) patients, a study suggests. B-cells are a type of immune cell best known for producing…

People with pediatric-onset multiple sclerosis (POMS) have a greater decline in cognitive function, and are more likely to experience cognitive impairment in adulthood, than those whose disease began when they were adults, a study reports. The study, “Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset…

New research suggests that rising blood pressure might be predictive of intracranial hemorrhage — bleeding in the brain, a serious and sometimes fatal condition — in people with multiple sclerosis (MS) who are receiving treatment with Lemtrada (alemtuzumab). The study, titled “Intracerebral haemorrhage during…

Startup company Oscine Therapeutics has received an investment from Sana Biotechnology to support the research and development of cell-based therapies for a variety of neurological disorders, including multiple sclerosis (MS). This venture is based on work done over the past several decades in the lab of Steve…

Scientists are zeroing in on mutations in a few genes that appear to be major risk factors for developing multiple sclerosis (MS). The results of their research suggest there are common biological pathways that cause the disease. The study, “Exome sequencing in multiple sclerosis families identifies 12…

Sutter Health, a California-based healthcare group, has partnered with the biotechnology company Roche to test a new mobile app that aims to improve monitoring of symptoms in people who have multiple sclerosis (MS). The app, called Floodlight, “may give neurologists access to meaningful, actionable patient data to…

Biopharmaceutical company Celgene has teamed up with the Multiple Sclerosis Association of America (MSAA) to launch a new initiative called MS MindShift: A New View of MS, aimed at educating the multiple sclerosis (MS) community on brain health. Although it’s an “important topic,” brain health “is not…

Investigational therapy evobrutinib, also known as M2951, can reduce relapse rates and brain lesions in people with relapsing forms of multiple sclerosis (MS), 48-week data from a Phase 2 clinical trial suggest. Updated results from the trial (NCT02975349) were presented at the recent 2019 annual…

As strange as it is to think about, many bacteria live in the human body, most of which are found in the gut (often referred to as the gut microbiome). These bodily roommates affect health in many ways that are only beginning to be understood. …

At the 2019 annual meeting of the American Academy of Neurology (AAN), Multiple Sclerosis News Today sat down with Bernd Kieseier, MD, global head of multiple sclerosis at Biogen, to discuss the company’s portfolio, latest data, and therapeutic development plans in the field of multiple sclerosis (MS). Kieseier said…

Early, one-year data from the Phase 3 CHORDS study show that Ocrevus effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of Neurology (AAN) in…

Exposure to interferon beta does not seem to increase the risk of complications during pregnancy in women with multiple sclerosis (MS), new research suggests. The data were presented in an oral presentation, “Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS…

New data suggests that treatment with Tysabri (natalizumab) in an extended interval dosing regimen is associated with a significantly lower risk of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), compared with the standard interval dosing. The data was presented by Lana Zhovtis Ryerson, MD, on May 7 at the 2019 …

New research suggests that even though pregnant women with multiple sclerosis (MS) are often viewed as high risk by their physicians, pregnancy  does not seem to increase the likelihood of adverse obstetrical outcomes for those patients or their babies. The research was presented at the 2019 Annual Meeting…

Infusible disease-modifying treatment — that is, therapies given intravenously — might have greater benefits for younger people with multiple sclerosis (MS) than oral ones, new research suggests. The research was presented at the ongoing American Academy of Neurology (AAN)’s annual meeting (May 4-10) by Brandi Vollmer,…

A trend of rapidly increasing costs for disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) appear to be the primary driver behind the overall rise in healthcare costs for people with MS, a study suggests. These data were presented in a…